DUBLIN–(BUSINESS WIRE)–The “Cell-based Assay Market Share, Size, Trends, Industry Analysis Report, By Product, By Type, By End-Use, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
The global cell-based Assay market size is expected to reach USD 32.23 billion by 2030.
The growing demand for cell-based assays in the biotechnology and pharmaceutical sector for drug development applications is expected to drive market growth. Furthermore, increasing penetration of the many non-curable diseases where vaccine development and drug discovery is one of the major factors driving demand.
In addition, the growing pharmaceutical needs to develop efficient drugs and vaccines across developing economies such as India, Brazil, Mexico, Japan, and China is likely to positively impact the demand for the product over the coming years. However, growing demand for the market to experiment on a live cell rather than using biochemical assay techniques to get accurate responses are anticipated to complement the growth of the market.
Cell-based assay Market Report Highlights
- Growing demand for the consumable segment in several applications, such as the production of cells, tissues, proteins, and mRNAs, is expected to drive product demand.
- The biopharmaceutical and pharmaceutical segment accounted for the highest revenue share in 2021 and is expected to continue its dominance owing to the high performance of cell proliferation and ensuring the accuracy of the provided samples.
- Drug discovery is expected to spearhead revenue growth due to the growing demand for cell-based assay vaccines and medicines than using biochemical assay techniques to develop drugs across developed as well as developing economies.
- Asia Pacific is expected to grow at a CAGR over the forecast period on account of several initiatives taken by biopharma and biotech companies in collaboration to develop new drugs across developing nations in the region, such as India and China.
The publisher has segmented the Cell-based assay market report based on Product, type, end-use, and region:
Cell-based Assay, Product Outlook (Revenue – USD Billion, 2018 – 2030)
- Reagent
- Assay Kits
- Reporter Gene Assays
- Cell Growth Assays
- Second Messenger Assays
- Cell Death Assays
- Toxicity Studies
- Pharmacodynamic Studies
- Pharmacokinetic Studies
Cell-based Assay, Type Outlook (Revenue – USD Billion, 2018 – 2030)
- Drug Discovery
- Toxicity Studies
- Pharmacodynamic Studies
- Pharmacokinetic Studies
- Basic Research
- ADME Studies
Cell-based Assay, End-Use Outlook (Revenue – USD Billion, 2018 – 2030)
- Pharmaceuticals & Biopharmaceuticals companies
- Contact Research Organizations
- Academic & Government Research Institutes
Cell-based Assay, Regional Outlook (Revenue – USD Billion, 2018 – 2030)
- North America
- U.S
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Research Methodology
4. Global Cell-based Assay Market Insights
5. Global Cell-based Assay Market, by Product
6. Global Cell-based Assay Market, by Type
7. Global Cell-based Assay Market, by End-Use
8. Global Cell-based Assay Market, by Geography
9. Competitive Landscape
10. Company Profiles
Companies Mentioned
- Charles River Laboratories Inc.
- Cell Signaling Technologies
- Cisbio
- Cell Biolabs Inc.
- Dickinson and Company
- Danaher Corporation
- GE Healthcare
- Lonza Group
- Beckman Coulter Inc.
- Bio-Rad Laboratories Inc.
- General Electric
- Merck KGaA
- Novartis AG
- PerkinElmer Inc.
- Promega Corporation
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/guxu1f
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900